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Abstract
Objective—To compare the rates of physical, psychiatric, and suicide-related events in
adolescents with MDD treated with fluoxetine alone (FLX), cognitive-behavioral therapy (CBT),
combination treatment (COMB), or placebo (PBO).
Method—Safety assessments included adverse events (AEs) collected by spontaneous report, as
well as systematic measures for specific physical and psychiatric symptoms. Suicidal ideation and
suicidal behavior were systematically assessed by self- and clinician reports. Suicidal events were
also reanalyzed by the Columbia Group and expert raters using the Columbia-Classification
Algorithm for Suicidal Assessment used in the U.S. Food and Drug Administration
reclassification effort.
Results—Depressed adolescents reported high rates of physical symptoms at baseline, which
improved as depression improved. Sedation, insomnia, vomiting, and upper abdominal pain
occurred in at least 2% of those treated with FLX and/or COMB and at twice the rate of placebo.
The rate of psychiatric AEs was 11% in FLX, 5.6% in COMB, 4.5% in PBO, and 0.9% in CBT.
Suicidal ideation improved overall, with greatest improvement in COMB. Twenty-four suicide-
related events occurred during the 12-week period: 5 patients (4.7%) in COMB, 10 (9.2%) in
FLX, 5 (4.5%) in CBT, and 3 (2.7%) in placebo. Statistically, only FLX had more suicide-related
events than PBO (p = .0402, odds ratio [OR] = 3.7, 95% CI 1.00–13.7). Only five actual attempts
occurred (2 COMB, 2 FLX, 1 CBT, 0 PBO). There were no suicide completions.
Conclusions—Different methods for eliciting AEs produce different results. In general, as
depression improves, physical complaints and suicidal ideation decrease in proportion to treatment
benefit. In this study, psychiatric AEs and suicide-related events are more common in FLX-treated
patients. COMB treatment may offer a more favorable safety profile than medication alone in
adolescent depression.
Keywords
major depressive disorder; fluoxetine; cognitive-behavioral therapy; adverse events
Placebo-controlled, randomized clinical trials (RCTs) are the gold standard for evaluating
efficacy and are also of critical importance in assessing safety and tolerability (March et al.,
2004). Although they provide substantial information on the measurement of safety, most
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clinical trials in pediatric psychopharmacology are generally poorly designed for this
purpose (Vitiello et al., 2003). For example, adverse events (AEs) in most of the pediatric
antidepressant trials conducted before the Treatment for Adolescents With Depression
(TADS) were primarily elicited by general inquiry (e.g., “Have you had any problems since
your last visit?”), with no systematic ascertainment of AEs. Only one pediatric depression
trial (Emslie et al., 2002) systematically collected information on AEs via a self-report
questionnaire at each visit. Recently, Greenhill et al. (2003) reported on AE elicitation
methods across pediatric psychopharmacological trials and found that the inconsistency
between trials likely impairs the ability to accurately and promptly identify drug-induced
AEs. Using the Safety Monitoring Uniform Report Form (SMURF; Greenhill et al., 2004),
which was designed to improve detailed elicitation of AEs associated with
psychopharmacological treatments, more AEs were identified by comprehensive body
system review than by general inquiry, suggesting that the latter may not be a sufficient
method for eliciting important and clinically-relevant AEs.
Clearly, medications can cause a variety of AEs involving many body systems. Major
depressive disorder (MDD) itself, however, is associated with high rates of physical
symptoms and behavioral changes, including pain, headaches, and stomachaches. Thus,
disentangling medication-related AEs from changes in illness is difficult, both with respect
to physical and behavioral symptoms, not to mention suicidality. Unfortunately, RCTs have
not generally required a thorough evaluation of physical symptoms at baseline, before
assessment of treatment-emergent AEs during acute treatment.
What do we know about AEs associated with selective serotonin reuptake inhibitors
(SSRIs)? A number of physical and psychiatric AEs, such as headache, nausea, abdominal
pain, insomnia, somnolence, tremor, and agitation, were more likely to occur with an SSRI
than with placebo, in several of the pediatric clinical trials (Emslie et al., 2002; Keller et al.,
2001; March et al., 1998; Wagner et al., 2003, 2004). In a few studies, more children on an
SSRI displayed manic symptoms than children on placebo, but the incidence was too small
to be statistically significant (Emslie et al., 1997).
Suicidality is generally too rare for clinical trials or even meta-analyses of clinical trials for a
single medication to be informative. However, in a recent pooled analysis of suicidality,
defined as suicidal thinking or behavior (attempts, preparatory behaviors, or ideation),
suicidal AEs occurred in approximately 4% of children randomized to an antidepressant as
compared to 2% on placebo (Hammad et al., 2006). Conversely, neither analyses of
epidemiological samples or large databases of naturalistically treated patients have found an
association between SSRI use and increased rate of completed suicide in any age group. In
fact, most have actually shown an association between SSRI use and decreasing rate of
suicide (Gibbons et al., 2005; Olfson et al., 2003). Similarly, the lack of positive toxicology
screening for antidepressants in completed youth suicide do not support the notion that
antidepressants are a consistent factor in death by suicide (Gray et al., 2002; Isacsson et al.,
2005; Leon et al., 2004). Considering the available data, it appears that antidepressant use is
correlated with increased suicidality in a small select group of individuals, but not correlated
with completed suicide.
The safety data from TADS are unique in several ways. First, it is the only trial that can
compare safety outcomes from medication, cognitive-behavioral therapy (CBT), the
combination of medication and CBT, (COMB), and medical management with pill placebo
(PBO). Therefore, not only does PBO provide a double-blind control, but the CBT-only arm
provides an additional nondrug comparison condition. Because MDD carries with it both
physical (e.g., insomnia) and psychiatric (e.g., irritability) symptoms, not to mention suicidal
behavior, which can be a symptom of MDD, it is often difficult to disentangle AEs from a
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lack of efficacy. Beyond the contrast with PBO, the availability of safety data from
treatment with CBT alone and in combination with fluoxetine (FLX) may shed additional
light on this issue. However, as highlighted in the introduction to this special section by
March et al., the clinicians and study participants were not blind to treatment in the COMB
and CBT arms, which undoubtedly affected not only efficacy, but also safety outcomes.
Second, this is the first CBT trial to assess AEs. Earlier psychotherapy trials did not assess
safety at all, so this trial provides preliminary reports on AEs collected by CBT therapists.
Third, TADS is the first trial to compare COMB treatment to monotherapies in depressed
adolescents. On the primary outcomes, TADS demonstrated that COMB was the most
effective treatment, followed closely by FLX; CBT alone was equivalent to PBO (TADS,
2004). Assessing the safety of individual treatment arms will provide additional information
for the risk-benefit ratio of each treatment. Finally, unlike most of the prior antidepressant
trials, which used only spontaneous reporting of AEs, TADS used two methods to elicit data
relevant to safety issues: spontaneous reporting of AEs and systematic assessments using
self-reports, clinician-rated and independent evaluator–rated measures of physical
symptoms, psychiatric symptoms, and suicide-related behaviors. Hence, although AE
reporting was not a primary outcome of the study, TADS is able to provide more details
about AEs than ordinarily available from RCTs.
In this study, which replicates and extends the earlier intent-to-treat acute treatment safety
outcomes (TADS, 2004), we tested whether the four treatment interventions of TADS differ
as to physical symptoms, general psychiatric symptoms (including symptoms of mania/
hypomania), and suicidal ideation and suicide-related AEs. For each of these safety
outcomes, a dual approach was taken, examining systematically administered rating scales
as well as individually reported AEs.
Method
The rationale, design, methods, and sample characteristics have been described in prior
reports (TADS, 2003, 2005) and are included in the Special Section introduction by March
et al. The patients were adolescents (N = 439), ages 12 to 17 years (mean ± SD, 14.6 ± 1.5
years), who were outpatients, with a primary DSM-IV diagnosis of MDD. The baseline mean
Children's Depression Rating Scale-Revised (CDRS-R) total score was 60.1, and 86% of the
sample were in their first episode of MDD. Patients were randomly assigned to receive one
of four possible treatment conditions: FLX (n = 109), CBT (n = 111), COMB (n = 107), or
PBO (n = 112). The trial was double blind for the FLX and PBO conditions, and single blind
for the CBT and COMB conditions.
The primary efficacy and safety outcomes paper (TADS, 2004) reported on the intention-to-
treat (ITT) sample composed of enrolled patients randomly assigned to one of the four
treatment arms, regardless of protocol adherence or completion. However, some participants
may have received out-of-protocol treatments (e.g., subjects assigned to CBT may have been
prematurely terminated if the addition of antidepressant treatment was clinically indicated or
vice versa). These subjects were allowed to continue in the study and are included in the ITT
analyses. In this paper, however, we focus on events occurring only within the assigned
treatment condition. To minimize confounding events associated with out-of-protocol
treatments, the focus here is on observed cases (OCs), defined as randomized patients who
at the time of the specified assessment or AE were still in their assigned treatment arm. That
is, the subject was still active in the study (had not dropped out), and the randomized
treatment had not been prematurely terminated (for ethical reasons, discontinued or
modified by the study clinician, such as adding one of the other treatments or an out-of-
protocol treatment) before the assessment or AE under consideration. However, baseline
rates of symptoms are the same as those reported in the primary acute ITT paper (TADS,
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2005), as all subjects remained within their assigned treatment arm at the baseline
assessment.
Safety Assessments
Spontaneous AE Reporting—At each treatment visit, the patient, and often his or her
primary caregiver, was asked through general inquiry how the teen was doing and if he or
she had experienced any problems since the last visit. An AE was defined as any
unfavorable medical change occurring post-randomization that was deemed to be clinically
significant, independent of relatedness to treatment. An AE was considered clinically
significant if it (1) was accompanied by interference in functioning or (2) required medical
attention. Such events would normally be considered of moderate severity or greater in
traditional RCTs of medication where AEs were classified as mild, moderate, or severe.
Each event was documented as to whether it was related to FLX or CBT. Using an AE form
that was completed at each treatment visit, pharmacotherapists captured AEs for all
medication patients (FLX, PBO, or COMB), and CBT therapists captured AEs for CBT only
patients. A serious AE (SAE) was defined using standard U.S. Food and Drug
Administration (FDA) language: Life threatening (at immediate risk of death), requires
hospitalization for any reason, results in persistent or significant disability or incapacity,
results in congenital anomaly or birth defect, results in death, or other significant medical
event, including cancer.
Systematic Assessment—Additional information regarding physical and psychiatric
symptoms was obtained using two systematically collected rating scales, the Physical
Symptoms Checklist and the Adolescent Depression Scale (ADS), which were developed
specifically for TADS.
Physical Symptoms Checklist (PSC)
The PSC, a symptoms checklist, was obtained at baseline and weeks 6 and 12. The PSC is a
47-item Likert-style self-report measure that ascertains both somatic and CNS signs and
symptoms. Ratings range from 0 to 3: 0 = not at all; 1 = just a little; 2 = pretty much; 3 =
very much. Patients were asked to rate symptoms present during the prior week. Excluding
items pertaining to female gynecological symptoms, a PSC total severity score was derived
from items 1 to 43. A principal components analysis (PCA) was conducted on these items
using a Varimax rotation method to derive factor-based scores. Initially, 11 factors were
identified by a minimum eigenvalue criterion of 1.0. Through the PCA process, 29 items
were retained in the final model based on 416 patients. Fourteen items were eliminated
because the item did not have a factor loading of 0.40 on any of the factors, the item did not
consistently load on one factor, or the item did not make conceptual sense within that factor.
Eight components that accounted for 60.5% of the variance were identified and labeled
sleep, upper respiratory, pain, cardiac, panic, elimination, nausea, and skin. Factor-based
scores were derived from those items within each component with a factor loading of 0.45
or greater. Headaches, which were not represented as a separate factor on the PSC but are
commonly reported as an AE of SSRI treatment, also are analyzed separately. (Requests for
the PSC should be directed to John March, M.D., at Duke University.)
ADS
The ADS is a 31-item Likert-style inventory that was completed at each treatment visit
based on information from the teen. The ADS systematically assessed depressive symptoms,
suicidality, symptoms associated with mania, and family, peer, and school functioning for
each subject. Patients were asked to answer yes or no whether each symptom and functional
problem was present in the week before the visit. The clinician then interviewed the subject
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to evaluate severity of each symptom. Severity ratings (0–3) were then coded for each ADS
item. Severity was assessed as not present (0), mild (1), moderate (2), or severe (3).
Pharmacotherapists rated patients randomized to any of the medication groups, and CBT
therapists rated the patients in the CBT-only group. If a subject in the COMB group saw a
CBT therapist on a day he or she did not see a pharmacotherapist, then the CBT therapist
completed the ADS. A mania total score (range 0–27) was calculated from the clinician
severity ratings for nine mania-related items. (Requests for the ADS should be directed to
John March, M.D., at Duke University.)
Suicidal Behavior Assessment
Spontaneous reports of suicide-related behaviors were captured through standard AE
reporting methods. Clinicians and site supervisors determined how to label these events,
which were then reviewed on a trialwide conference call, and finally recoded for consistency
by three raters at the TADS coordinating center. Because of the controversies surrounding
SSRIs and suicidality, the FDA commissioned suicidology specialists at Columbia
University to conduct a reclassification of all possibly suicidal events (suicidal thoughts or
behaviors), applied by an internationally recognized expert panel, across all clinical trials of
antidepressants (Posner et al., 2004). The group developed a highly reliable classification
system that distinguishes suicidal from nonsuicidal events known as the Columbia
Classification Algorithm of Suicide Assessment. To provide consistency across pediatric
trials, the TADS investigators requested the Columbia-led group reclassify the TADS harm-
related events, not only the events within the FLX and PBO groups (which had already been
done for the FDA), but also to review and classify the events within COMB and CBT-only
groups.
Both electronic and manual searches of all potential harm-related events were conducted
using the search strategy conducted for the recent FDA analyses. In general, text strings
such as “suicide” and “overdose” were assessed. Additional details about specific text
strings used are available on the Journal's Web site at www.jaacap. com via the Article Plus
feature. Narratives for all possible suicidal and aggressive events were submitted to
Columbia, where each event was reviewed and coded by two independent raters from the
expert panel. The Columbia coding system used seven codes for assessing all suicidal and
harm-related events. Three of the codes were considered suicidality (ideation and behavior:
suicide attempt (FDA Code 1: any self-injurious behavior associated with some intent to
die), preparatory actions toward imminent suicidal behavior (FDA Code 2), and suicidal
ideation (FDA Code 6: includes passive as well as active suicidal ideation). A fourth code,
self-injurious behavior with unknown intent (FDA Code 3), was included in sensitivity
analyses in the FDA work as possibly suicide-related events. These classification categories
are reported here.
Suicidal Ideation Questionnaire: Grades 7 to 9 (SIQ-Jr)—The SIQ-Jr (Reynolds,
1987) is a 15-item self-report focusing on suicidal thinking. Patients completed the SIQ-Jr at
baseline and weeks 6 and 12. A total score ᚣ31 on the SIQ-Jr is considered a flag indicating
elevated suicidal risk. In addition, a score of 5 or 6 on two or more items of a subset of
individual items (items 2–4, 7–9) is also considered a flag for potentially serious self-
destructive behavior.
CDRS-R—The CDRS-R (Poznanski and Mokros, 1996) is a 17-item clinician-rated
depression severity scale that was completed by independent evaluators blind to treatment
assignment at baseline and weeks 6 and 12. Item 13 on the CDRS-R evaluates suicidal
behavior and is rated on a scale of 1 to 7. Scores of 1 to 2 are suggestive of little or no
suicidal thinking or behavior; a score of 3 suggests thoughts of suicide or suicidal ideation.
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Scores of 5 or greater suggest significant interference in functioning caused by suicidal
thinking or behaviors.
Statistical Methods
As stated previously, data are included only for patients who were active in their assigned
treatment arm at the time of the assessment. For example, if a subject was prematurely
terminated from or dropped out of their assigned treatment arm, then subsequent AEs/SAEs
would not be addressed in this article. In this way, only events occurring within the actual
treatment assignment are analyzed. The rationale for this approach is that some patients
sought or were provided additional or alternative treatment options following premature
termination from their assigned treatment. For example, a subject assigned to CBT could be
prematurely terminated because of lack of benefit and, as a result, begin treatment with
FLX, yet continue to receive study CBT and complete study assessments. By censoring the
data to use OCs only, events cannot be misattributed to the treatment in the original study
arm.
Tests for differences in proportions (e.g., Ȥ2 and Fisher exact tests) were used to examine
between-treatment differences in event rates derived from the spontaneous AE reporting and
the systematic assessments. Odds ratios (ORs) and 95% confidence intervals (CIs) were also
calculated for event rates in order to measure the relative risk in an active treatment arm
when compared to PBO or in SSRI-treated cases relative to non-SSRI treated cases. Linear
random regression models for repeated measurements were employed to test for between-
treatment differences in rate of change (slope) across time as well at the end of the acute
treatment period (week 12) in the SIQ-Jr and PSC total scores. Fixed effects within the
model were treatment, the natural log of time, and treatment × time, and patient and patient
× time were included as random effects. Nondirectional statistical tests were conducted and
the Į level for each omnibus test was 0.05. If a significant treatment effect or treatment ×
time interaction was detected, a closed testing approach was applied to the paired contrasts
and the level of significance for each between-treatment comparison was set at .05. When
the treatment effect or treatment × time interaction was not significant at the .05 level, paired
contrasts were conducted, but a sequential rejective method was applied in order to protect
the type I error rate (Koch and Gransky, 1996).
Results
Patient Disposition
TADS treatments proved acceptable and tolerable. Of the 439 randomized patients, 359
(81.8%) remained in their assigned treatment arm through 12 weeks of acute treatment,
although eight of these missed the week 12 assessment visit. The proportion of patients who
remained in the assigned treatment arm was greater with fluoxetine-treated patients.
Specifically, 86.0% in COMB, 83.5% in FLX, 78.4% in CBT, and 79.5% in PBO were in
their assigned treatment arm at the week 12 assessment point. There were no significant
differences in discontinuation rate (dropout and/or premature termination) between the
treatment arms. The mean maximal dose (in milligrams) prescribed was 27.9 ± 8.4 for the
COMB arm, 32.8 ± 10.6 for the FLX arm, and 33.5 ± 9.6 for the PBO arm.
Physical Symptoms
Baseline rates of self-reported physical symptoms (i.e., not including psychiatric symptoms
or self-harm) were similar across the four groups and were quite high. For example, 53.8%
of the sample reported trouble sleeping, 33.8% reported headaches, and 26.6% reported
stomach pain or ache before initiation of treatment. Rates of each physical symptom from
the PSC, a self-report checklist, can be found in the Article Plus material. Across the entire
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sample, girls had higher mean PSC total scores than boys (24.7 ± 17.9 versus 18.1 ± 15.4; p
< .0001).
There was a decrease in the total severity of self-reported physical symptoms across all
groups during the 12 weeks of acute treatment. Interestingly, COMB, FLX, and PBO all had
significantly lower total PSC scores at week 12 (11.0 ± 8.2, p = .0036; 13.0 ± 10.5, p = .
0328; and 12.3 ± 8.9, p = .0280, respectively) than CBT (18.5 ± 17.5). There were no
significant differences between the other three groups.
On the eight factor–based scores (sleep, upper respiratory, pain, cardiac, panic, elimination,
nausea, and skin), each of the four treatment groups showed improvement on all eight
factors. Participants receiving CBT showed less improvement over time than the other three
groups on all eight factors, although most did not reach statistical significance. The only
factor to show a treatment × time interaction was pain, with participants receiving either
FLX or COMB significantly more improved than those receiving CBT (p = .0017 and p = .
0011, respectively).
Treatment-Emergent Physical Symptoms and AEs—Two hundred eleven
spontaneous (but not necessarily related to treatment) physical AEs that required medical
attention or caused dysfunction were reported in 113 patients during the course of the 12
weeks of acute treatment. No significant differences were found in number of patients
reporting AEs between the three groups receiving pills: FLX (n = 35), COMB (n = 37), or
PBO (n = 34). However, more events were reported by those in the FLX-only group (within
similar numbers of patients) compared to those receiving either COMB or PBO (FLX = 81,
COMB = 61, PBO = 60). Relatively few AEs were reported by CBT therapists (n = 9)
compared with pharmacotherapists (n = 202).
Sedation, insomnia, vomiting, and upper abdominal pain were reported in at least 2% of
patients and at rates at least two times greater with FLX and/or COMB than PBO (Table 1).
Nonetheless, these AEs were infrequent (<5%). The only AE occurring in more than 5% of
patients was headache, which occurred at similar rates in those treated with FLX (11.9%),
COMB (6.8%), and PBO (10.7%). As stated, few AEs were reported for the CBT group, and
no symptoms were reported at a greater rate with CBT than with PBO.
All items on the PSC were analyzed for worsening or emergence of symptoms, with the
caveat that treatment-emergent symptoms on the PSC were not necessarily coded as AEs by
spontaneous report. To determine worsening or emergence of symptoms, all patients
receiving a 0 or 1 (0 = not at all, 1 = just a little) at baseline and increasing to a 2 or 3 (2 =
pretty much, 3 = very much) at week 6 or 12 were identified, as well as those who increased
in severity from a 2 (pretty much) to 3 (very much). Based on PSC self-report, treatment
with fluoxetine did not lead to significantly higher rates of symptom worsening or
emergence on any physical symptoms. Table 2 illustrates the rates of worsening or
emergence of symptoms based on self-report for all four treatment groups. Furthermore, in
comparing only the double-blind treatment groups (FLX versus PBO), there were no
significant difference on emergence or worsening of any physical symptoms.
Psychiatric Symptoms
Clinical Global Impression-Improvement (CGI-I) ratings were completed at week 6 and
week 12 by independent evaluators. CGI-I was based on improvement of depression. Three
patients (2.8%) on FLX and two (1.9%) on COMB received a 5 or greater, indicating
slightly worse (score of 5), much worse (6), or very much worse (7) at either week 6 or 12,
compared to 10 (9.0%) on CBT and 7 (6.3%) on PBO. There was a statistically significant
difference between subjects receiving fluoxetine (FLX and COMB) and subjects not
Emslie et al. Page 8
J Am Acad Child Adolesc Psychiatry. Author manuscript; available in PMC 2012 February 23.
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t
receiving FLX (CBT and PBO; p = .01); however, the individual arms were not compared
because the frequencies were too small in each arm. These rates are based on OCs and are
similar to the ITT analyses presented by March (2005).
Worsening of the CGI-S score produced similar results. A worsening of at least 1 point from
baseline to either week 6 or 12 was found in 2 (1.8%) patients receiving FLX, 2 (1.9%) in
COMB, 5 (4.5%) in CBT, and 9 (8.0%) in PBO.
Treatment-Emergent Psychiatric Symptoms and AEs—Table 3 presents rates for
psychiatric-related AEs (spontaneous reports occurring at any time during the 12 weeks)
grouped by clusters: mania spectrum, irritability/depression spectrum, agitation spectrum,
anxiety, and other. There were more psychiatric AEs in patients treated with FLX (either
alone or in combination) than in patients treated with CBT or PBO. Within mania spectrum
(mania, hypomania, and elevated mood), one (0.92%) subject assigned to FLX developed
mania and four patients developed hypomania (one COMB, one PBO, and two FLX). One
subject was reported to have elevated mood (FLX). On the irritability/depression spectrum
(hypersensitivity, irritability, anger, worsening of depression, and crying), two patients
developed hypersensitivity (FLX), two irritability (one COMB, one FLX), one anger (FLX),
one worsening of depression (PBO), and one crying (COMB). A total of five patients
exhibited symptoms in the agitation spectrum (agitation, akathisia, nervousness, restlessness,
and hyperactivity), including one subject with akathisia (COMB), one with nervousness
(PBO), one with hyperactivity (FLX), and two (FLX, PBO) reporting restlessness. Three
patients reported anxiety/panic symptoms, including two with panic attacks (FLX, CBT) and
one with anxiety (FLX). Three patients developed tremor (two FLX, one COMB), one
developed “abnormal behavior” (PBO), and one subject reported “feeling spacy” (COMB).
More patients on FLX alone had psychiatric AEs than those on PBO; however, the numbers
are too small to detect statistical significance.
Mania symptoms were also assessed using the ADS. The ADS is initially completed by the
teen, who is asked simply whether a symptom is present. Clinicians then interviewed the
teen about symptoms and rated the severity of each item (0–3), for a mania subscale score of
0 to 27. The majority of adolescents (83.4%) reported the presence of at least one symptom
within the mania items on the ADS, and 59% reported presence of at least two symptoms.
The most common symptoms endorsed by teens as positive were “having trouble paying
attention or keeping your mind on what you are doing” (68.8%), “racing thoughts or having
too many ideas in your head at one time” (33.5%), and “talking on and on, or talking very
fast” (23.8%).
At baseline, mean (± SD) mania baseline severity scores were very low and similar for all
groups: COMB = 2.6 ± 2.4, FLX = 2.2 ± 2.2, CBT = 2.5 ± 2.4, and PBO = 2.2 ± 2.3 (total
sample 2.4 ± 2.3; range 0–12).
During the course of treatment, all four treatment groups showed a decrease in the total
mania score on the ADS during the 12 weeks of treatment; final ADS Mania subscale scores
were 0.5 ± 0.8 COMB, 1.1 ± 1.0 FLX, 1.1 ± 0.1 PBO, 1.0 ± 1.2 CBT (total sample, 0.9 ±
1.4). Total scores for COMB at endpoint were significantly lower than FLX (p = .013), PBO
(p = .003), and CBT (p = .012).
Change scores on the ADS Mania subscale were constructed to assess for emergence or
worsening of behavioral symptoms during treatment. Only subjects with at least two mania
total scores were included (n = 424). A total of 65 of 424 (15.3%) adolescents had an
increase of 3 points or more during the 12 weeks of treatment: 20% (n = 21) COMB, 14.2%
(n = 15) FLX, 12.3% (n = 13) CBT, and 15.0% (n = 16) PBO. Most increases were with
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trouble paying attention (mean increase of 0.71 ± 1.3), racing thoughts (mean increase of
0.57 ± 0.9), excessive talking/talking very fast (mean increase of 0.49 ± 0.7), increase in
activities (mean increase 0.49 ± 0.9), and impulsivity (mean increase 0.49 ± 1.1).
Of the five patients who developed mania or hypomania based on AE reporting, three were
on FLX, one was on COMB, and one was on PBO. The three on FLX had high baseline
ADS mania symptom scores (ᚣ5). The patients on COMB and PBO who developed
hypomania had baseline ADS scores of 0 and 1, respectively. Thirty-eight patients
randomized to FLX treatment (with or without CBT) had an ADS Mania subscale total score
ᚣ5 at baseline. Thus, most (92%) patients with elevated ADS Mania scores tolerated FLX
treatment without developing additional symptoms of mania or hypomania.
Suicidal Ideation and Suicide-Related AEs
Suicidal ideation was common at baseline, with 29.2% of patients reporting significant
suicidal ideation on a self-report measure (SIQ-Jr). Based on independent evaluator
assessment, 21.4% of patients reported some suicidal behavior at baseline (CDRS-R item 13
ᚣ3). The COMB group reported more suicidal ideation at baseline on the SIQ-Jr, compared
with the other treatment arms, although this difference did not reach statistical significance.
Suicidal ideation improved across all groups during acute treatment (Fig. 1). Improvements
in suicidal ideation have been reported previously (TADS, 2004), and the OCs findings were
similar. Adjusted mean scores at the end of 12 weeks were not statistically different between
the four individual treatment groups (COMB: 10.9 ± 0.3, FLX: 13.7 ± 0.2, CBT: 11.3 ± 0.3,
PBO: 14.5 ± 0.6). However, as the group in COMB started with higher baseline severity
scores, the overall improvement in suicidal ideation was greater for COMB than FLX (p = .
004), CBT (p = .04), and PBO (p = .02).
Treatment Emergent Suicide-Related Behaviors—Self-reported emergence or
worsening of suicidal ideation on the SIQ-Jr was also analyzed. Emergence or worsening of
suicidal behavior was defined as any subject whose baseline total score had not been ᚣ31 on
the SIQ-Jr, but who had a total score ᚣ31 at either week 6 or 12. A total of 4.8% (18/374)
patients showed emergence or worsening of suicidal behavior based on this self-report: 2.2%
(2/93) in COMB, 7.3% (7/96) in FLX, 2.2% (2/93) in CBT, and 7.6% (7/92) in PBO. There
were no significant differences between the four individual groups.
Clinician ratings were also analyzed for worsening and emergence of suicidality (CDRS-R
item 13). To be conservative, any worsening of 1 or more points was considered worsening
of suicidality. Five percent of COMB patients, 13.4% on FLX, 15.2% on CBT, and 7.2% on
PBO showed worsening of suicidality from baseline to either week 6 or 12 on this measure.
For emergence of suicidality, any subject who reported little or no suicidal ideation or
behavior at baseline (score of 1 or 2), but who worsened to marked suicidal ideation/
behavior or worse (score ᚣ5) at week 6 or 12 was reviewed. Based on these more stringent
criteria, none of the COMB treated patients reported emergence of suicidality, compared to
3.7% on FLX, 1.3% on CBT, and 2.6% on PBO. There were no statistically significant
differences between groups on worsening of suicidal ideation or behavior based on self- or
clinician reports.
Spontaneously Reported Suicide-Related Events—Suicide-related AEs were
reanalyzed using the Columbia rating format. In instances where a subject had more than
one suicide-related event, this subject was represented only once in the analysis and the most
severe code was used, as in the FDA safety analysis. An event was rated as a suicide attempt
if there was self-injurious behavior with some intent to die. Following the format used in the
FDA analyses, suicide attempts (Code 1), as well as preparatory actions toward imminent
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suicidal behavior (Code 2), and suicidal ideation (Code 6) were considered suicide-related
events in the primary analyses. There were no incidences of preparatory actions toward
imminent suicidal behavior (Code 2) in the TADS. Additional sensitivity analyses also
included self-injurious behavior with unknown intent (Code 3). Table 4 details the number
of events for each group.
Based on the primary analyses (Codes 1, 2, and 6), 5 patients (4.7%) in COMB, 10 (9.2%) in
FLX, 5 (4.5%) in CBT, and 3 (2.7%) in PBO had suicide-related events reported during the
12-week period. FLX alone had more incidences of suicide-related events than PBO (p = .
0402, OR 3.7, 95% CI 1.00–13.7). However, patients taking FLX with CBT (COMB) had
the same number of events as those with CBT and no medication. Very few actual suicide
attempts occurred: two in COMB, two in FLX, one in CBT, and none in PBO. These rates
are not statistically different between the four treatment groups. In the original TADS report
(TADS, 2004), four COMB patients were reported as making a suicide attempt; however,
one of these patients did so after prematurely terminating from the assigned treatment arm,
and one subject was not coded by the Columbia group as making a suicide attempt, so these
subjects are not counted here.
Table 5 provides details of the 24 events found in the sensitivity analysis (suicide attempt,
preparatory acts, suicidal ideation, and self-injurious behavior intent unknown) that
occurred. Fifteen of the 24 events were identified as SAEs, and 10 of subjects required
hospitalization. Approximately one third (38%) of the patients continued in the assigned
treatment arm following the suicidal event. However, most of those with an actual suicide
attempt did discontinue TADS treatment or sought additional treatment (four of five). Of
those who experienced the 24 events, just over half were male (n = 14). More than half of
the patients had at least one comorbid psychiatric disorder (58.3%), and 10 (41.7%) had
reported high levels of suicidal ideation at baseline (either by total score or on at least two
planning items on the SIQ-Jr scale).
Clinical characteristics before the attempt also varied. Most patients (18/24; 75.0%) were
considered to be at least moderately depressed (CGI-S ᚣ4) at the visit before the suicidal
event. Only six patients were considered mildly ill or better (CGI-S ᚢ3). In two of these
cases, the last available CGI-S score was about 3 weeks before the attempt, so depression
severity immediately before the attempt is unknown. In addition, psychosocial stressors
immediately before the event were reported by the study clinician in 70.8% of the narratives.
Seven patients (29.2%) had an ADS mania score ᚣ3 within 2 weeks before the event, which
is slightly higher than the mean baseline score for all patients. However, none of the patients
who developed mania, hypomania, or elevated mood (n = 6) had a suicidal event.
The timing of the suicide-related event was similar among the groups, with slightly longer
mean time to event in the COMB group: 52.0 ± 20.8 days on treatment for COMB, 38.0 ±
21.7 for FLX, 45.4 ± 26.7 for CBT, and 32.0 ± 15.0 for PBO. Table 5 includes the number
of days from treatment initiation to the suicidal event (Days on Tx). Most (70.8%) had been
in treatment for at least 1 month before the event. For those receiving FLX (with or without
CBT), 11 of 16 (68.8%) had been on the antidepressant for at least 1 month; six of eight
(75.0%) of those not on medication (CBT or PBO) had been in treatment for at least 1
month. For those on FLX, the dose varied, but was consistent with the dosing for the entire
subject population. Only four patients (16.7%) had had a recent dose change before the
event. More specifically, two in COMB and one in PBO increased to 30 mg and one in FLX
increased to 20 mg within 7 days before the event). Neither of these patients made a suicide
attempt.
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For those making a suicide attempt, four of five patients had high rates of suicidal ideation at
baseline; four had expressed psychosocial stressors before the attempt. All five had been in
treatment for at least 1 month before the attempt, and none of the adolescents in the
medication groups had had a recent dose change before the attempt.
Discussion
The TADS was the first study to compare efficacy and safety of FLX, CBT, their
combination, and placebo in the treatment of pediatric depression. The study is also among a
relatively small number of trials that used systematic assessment of AEs, as well as the
general inquiry used in most clinical trials. Over 80% of the adolescents completed 12
weeks of treatment in their assigned treatment arm, indicating the TADS treatments were
generally acceptable and tolerable.
Depressed adolescents had high rates of physical symptoms at baseline by systematic
assessment, and as depression improved, physical symptoms also improved. Careful
assessment of physical symptoms before initiating treatment is important to establish a
baseline and identify change with treatment.
Systematic review of symptoms and spontaneous AE reporting produced quite different
results, with systematic review eliciting substantially more positive symptoms. This is
consistent with findings by Greenhill et al. (2004). Unlike many clinical trials, the definition
of an AE in TADS included the requirement that the event be “clinically significant” (i.e.,
characterized by either interference in functioning or need to seek medical attention). It is
unclear whether this change in definition affected the results between treatment conditions,
but it is possible because there were fewer AE reports overall in this trial than in other
clinical trials.
The difference in systematic versus spontaneous symptom reporting was most evident in the
CBT group, where only nine spontaneous AEs were reported in the 111 patients randomized
to that treatment group. Through systematic review, however, the CBT group had higher
total adverse symptom scores at weeks 6 and 12 than the other three groups, suggesting
under-reporting of AEs by CBT therapists. Hence, to compare AEs across treatment groups,
future trials comparing different treatment modalities would profit from including a
structured systematic assessment of AEs.
Few patients showed a worsening of psychiatric symptoms during the trial based on
spontaneous report. Specifically, 22 showed a worsening of depression symptoms, with only
three on FLX and two on COMB showing a worsening of depression. However, more
patients on FLX reported psychiatric symptoms overall than those in COMB, PBO, or CBT.
The numbers were too small, however, to detect statistical differences. Only one teen
developed mania during the course of the study (in FLX), and the development of
hypomania was also rare (one COMB, two FLX, one PBO). Interestingly, COMB did not
have significantly more psychiatric AEs or more mania than PBO. It remains unclear how or
why patients receiving FLX in combination with CBT had fewer psychiatric AEs than those
receiving FLX alone. Is it CBT that provides protection or is it a dosing issue? The mean
dose for the combination group was lower than in FLX alone, but it is unclear whether this
led to a difference in physical or psychiatric event reporting.
Despite excluding patients in imminent danger of attempting suicide, rates of suicidal
ideation were quite high at baseline (29.2%). Suicidal ideation improved over time, and only
9.6% had suicidal ideation at the end of 12 weeks. The COMB group had higher baseline
severity scores, so the overall improvement in suicidal ideation was greater for COMB than
the other three groups.
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During the study, there were 24 reports of suicidal behavior (attempt, preparatory actions,
self-injurious behavior with intent unknown, or suicidal ideation). Only five suicide attempts
were reported during the acute trial in patients remaining in their assigned treatment arm
(two COMB, two FLX, one CBT). Unlike the two previous placebo-controlled trials of FLX
(Emslie et al., 1997, 2002), there were significantly more suicide-related events reported in
patients taking FLX than those on PBO. The majority of the suicide-related events in the
trial consisted of suicidal ideation (n = 18). Patients who had suicide-related events had a
high number of risk factors, including moderate depression at the time of the event,
psychosocial stressors before the event, high levels of suicidal ideation at baseline, and so
forth. In spite of the common belief that suicide-related events occur shortly after initiating
antidepressant treatment, in this study most events occurred over 1 month after initiating
treatment, and this was consistent across all four groups.
It is often difficult to disentangle the factors that precipitate either suicidal ideation or
suicide attempts. Is it a failure to treat the depression? Is it increased activation or agitation?
Does the medication induce suicidal behavior? If it is simply a result of receiving
medication, both FLX with and without CBT would be expected to have similar rates of
suicide-related events; however, in this study, FLX monotherapy had more events than
COMB, yet COMB had no more suicide-related events than CBT without medication. It is
possible that CBT provides skills (e.g., coping skills, family conflict management) that can
be used to reduce suicide-related events. It is also possible that the increased medication
dose in the FLX-alone group influenced suicidal behavior. Finally, it may be that the
reduced rate of suicide-related events in the combination group was related to the greater
overall benefit and improvement of depression in that group. Other factors that may affect
suicidal behavior are stressors and behavioral activation. TADS did not have adequate
measures of these factors, so it is unclear what impact these factors may have had.
Limitations
As noted in the Introduction to this special section by March et al., one important limitation
to the TADS was that patients and clinicians in the COMB and CBT groups were not blind
to treatment assignment, whereas the FLX and PBO arms were double blind. It is possible
that spontaneous AE reporting was affected by this study design. Furthermore, subjects in
COMB treatment had more frequent sessions, as these patients received full CBT sessions
plus full psychotherapy sessions. Increased frequency of visits may have improved the
safety outcomes for this treatment arm.
Another limitation is that CBT therapists have not historically assessed AEs per se, which
was evident in this trial with so few reports of AEs in that group. It is likely that raters of
different disciplines (e.g., medicine versus psychology), the amount of contact a rater has
with subjects and the raters' awareness of treatment conditions may affect his or her
assessment of safety. For example, discussion among CBT therapists revealed that general
inquiry was at times either skipped or minimized in order to maximize the time available for
topics and goals directly relevant to the CBT intervention. If CBT or other psychotherapy is
evaluated as a comparator to medication in future research, it is essential that systematic
assessment of these events be conducted. As seen with the self-report assessment on TADS,
rates of physical symptoms were substantially more frequent than spontaneous AE reports,
which is consistent with a recent study by Greenhill et al. (2004). Furthermore, systematic
assessment should be done at each visit. In this study, one of the limitations was that the
systematic assessment of physical symptoms was only done at weeks 6 and 12 of treatment.
A subject who experienced one of these symptoms during the interim period may not have
reported the event at the time the information was collected at the assessment visit.
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Another limitation of the TADS trial was that other than mania, there was no systematic
assessment of psychiatric symptoms, such as aggression, agitation, akathisia, and
disinhibition, which are potentially associated with FLX. Because TADS provides only
spontaneous reports of these events, which were rare and not associated with suicidality, a
definitive answer to the question of whether an association between psychiatric symptoms
and suicide-related events exists is not possible.
The TADS trial did provide a systematic measure of mania symptoms through weekly
monitoring visits. However, the method used (ADS mania subscale) is not a standardized
scale. Furthermore, it was noted by clinicians (both pharmacotherapists and CBT therapists)
that scoring of the items was inconsistent, varying from clinician to clinician. Further
complicating interpretations of data collected with this scale is that some of the endorsed
items may have been the result of disorders other than mania/hypomania. For example,
inattention, which was one of the most common positive items on the subscale, may have
been caused by depression or ADHD, and it is not clear that clinicians discriminated in
scoring based on cause of the symptom. Thus, if the symptom was problematic for the
patient, it was likely to be coded as positive on the mania subscale, despite the fact that there
may have been no other symptoms of mania or activation for that patient. This is likely to
have resulted in selected items on this scale being evaluated as positive even in adolescents
without mania or hypomania. As such, the results from the ADS mania subscale should be
interpreted with caution. Still, TADS is the first depression trial to provide any systematic
assessment of mania-related symptoms. Future studies will benefit from incorporating
systematic measure of these symptoms both at baseline and throughout treatment.
Although this is the first study to report substantial detail regarding suicide-related events
occurring within the treatment trial, several unanswered questions remain. First, although
adolescents completed a self-report about suicidal ideation at baseline, specific details about
past suicidal behavior were not collected. For future studies, detailed prospective assessment
of suicidal behavior is needed to better evaluate treatment-emergent suicidality. In this
study, there were no significant differences between the four treatment groups on emergence
or worsening of suicidal ideation or behaviors based on self- and clinician-report. However,
these systematic assessments were only conducted at weeks 6 and 12, and only provide a
snapshot of the suicidality at the time of those assessments. Another limitation related to
suicidality assessment involved the recording of the actual suicide events. Suicidal behaviors
were identified and recorded based on site discretion, which has been reported as one of the
limitations of the safety outcomes in most clinical trials. To address this problem, all
potentially suicide-related events were reevaluated by a national expert panel; thus, events
were not simply interpreted by the site. However, the description of events provided to
national expert panel were those submitted regarding the event in question, and the level of
available information on these events varied greatly. Therefore, in some instances, limited
information was available to the group to determine the classification. Future studies may
want to conduct more intensive and standardized assessment of suicide-related AEs in order
to complete a more comprehensive assessment.
Finally, suicidal events are a very low base-rate phenomena, which require extremely large
samples for study. The number of suicide-related events in the present study was small,
although they were more frequent than in two prior trials of FLX trials. Several possible
explanations for the increase in this study exist. First, it is possible that the increased
incidence was by chance. Second, it is possible that it is related to dosing (the prior two FLX
trials were 20-mg fixed-dose studies). Third, this study included only adolescents, whereas
the prior two trials included children as well. Adolescents have a higher base rate of suicidal
behavior than children, which could also account for the increase.
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Finally, the increased rate of suicidal behavior in this trial may be a result of the longer trial
length (12 weeks versus 8–9 weeks). As mentioned, more systematic assessment of the
possibly related behavioral activation symptoms mentioned by the FDA in the black box
warning will help disentangle these unknowns. This study was simply too small too answer
these questions.
Clinical Implications
Although research in the treatment of pediatric depression has expanded significantly over
the past decade, TADS is the first study to directly compare pharmacological and
psychosocial treatment modalities. As more trials are being published on this population, the
tendency may be for clinicians to focus primarily (or exclusively) on the efficacy results; yet
the safety results are equally important, if not more so.
Clinicians treating depressed youths should note that these patients report relatively high
incidences of physical symptoms, as has been described in several reports (Lewinsohn et al.,
1996; Rhee, 2003; Williams et al., 2002; Yates et al., 2004). It is possible that depressed
adolescents visiting their pediatrician or primary care physician may present with physical
complaints rather than specific mood symptoms. It is also important to note that physical
symptoms decreased as depression improved.
Given the recent FDA warning, it is important to routinely assess psychiatric symptoms,
such as hostility, agitation, and mania. Based on the present study, psychiatric AEs causing
moderate to severe impairment are rare, but do occur. It is possible that psychiatric AEs are
dose related or that concurrent psychotherapy offers some protection against such changes,
but this area needs further study.
Finally, despite the fact that all of the treatment arms were effective in reducing suicidal
ideation, individual teens in clinical trials such as TADS will express suicidal ideation and
make suicide attempts in the context of preexisting suicidal ideation, worsening of
depression, stressful life events, and perhaps also in the context of improving depressive
symptoms. Clearly, suicidal thinking and behavior need to be assessed carefully, both before
and prospectively during treatment. Clear understanding and identification of any event are
also necessary. That is, clinicians need to collect adequate information about the event to
determine whether it was suicidal ideation, self-injurious behavior without intent to die, or
an actual suicide attempt (suicidal ideation with intent to die). Based on guidelines from the
FDA, patients beginning medication treatment should be observed closely for clinical
worsening, suicidality, or unusual changes in behavior (face-to-face with the clinician
weekly for 4 weeks of treatment, then every other week for 1 month, and again at 12 weeks).
In addition, parents and teens should be given adequate information about risks associated
with antidepressants and the importance of parental monitoring of the youths. Furthermore,
in this study, suicide-related events often occurred more than 1 month after treatment began,
so continued monitoring of suicidal ideation and behavior throughout the course of
treatment is important. In summary, this article, combined with the TADS primary efficacy
paper (TADS, 2004), provides important information for clinicians to better help their
patients and families make informed assessment of the risk-benefit ratio when treating
adolescent depression.
Acknowledgments
The authors thank and acknowledge the independent expert raters from the Columbia Suicidality Classification
Project: David Brent, M.D., Greg Brown, Ph.D., David Rudd, Ph.D., Cheryl King, Ph.D., Anthony Spirito, Ph.D.,
A.B.P.P., Peter Marzuk, M.D., Patrick O'Carroll, M.D., M.P.H., Annette Beautrais, Ph.D., Kees Van Heeringen,
M.D., Ph.D., and Alec Miller, Psy.D.
Emslie et al. Page 15
J Am Acad Child Adolesc Psychiatry. Author manuscript; available in PMC 2012 February 23.
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t
TADS is supported by contract N01 MH80008 from the National Institute of Mental Health to Duke University
Medical Center (John S. March, Principal Investigator).
References
Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebo-controlled study of
fluoxetine in depressed children and adolescents. Arch Gen Psychiatry. 1997; 54:1031–1037.
[PubMed: 9366660]
Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in
children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child and
Adolesc Psychiatry. 2002; 41:1205–1215. [PubMed: 12364842]
Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant medication use
and rate of suicide. Arch Gen Psychiatry. 2005; 62:165–172. [PubMed: 15699293]
Gray D, Achilles J, Keller T, et al. Utah youth suicide study, phase I: government agency contact
before death. J Am Acad Child Adolesc Psychiatry. 2002; 41:427–434. [PubMed: 11931599]
Greenhill L, Vitiello B, Riddle M, et al. Review of safety assessment methods used in pediatric
psychopharmacology. J Am Acad Child Adolesc Psychiatry. 2003; 42:627–633. [PubMed:
12921469]
Greenhill LL, Vitiello B, Fisher P, et al. Comparison of increasingly detailed elicitation methods for
the assessment of adverse events in pediatric psychopharmacology. J Am Acad Child Adolesc
Psychiatry. 2004; 43:1488–1496. [PubMed: 15564818]
Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant
drugs. Arch Gen Psychiatry. 2006; 63:332–339. [PubMed: 16520440]
Isacsson G, Holmgren P, Ahlner J. Selective serotonin reuptake inhibitor antidepressants and the risk
of suicide: a controlled forensic database study of 14 857 suicides. Acta Psychiatr Scand. 2005;
111:286–290. [PubMed: 15740464]
Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major
depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 2001; 40:762–772.
[PubMed: 11437014]
Koch GG, Gransky SA. Statistical considerations for multiplicity in confirmatory protocols. Drug
Information J. 1996; 30:523–534.
Leon AC, Marzuk PM, Tardiff K, Teres JJ. Paroxetine, other antidepressants, and youth suicide in
New York City: 1993 through 1998. J Clin Psychiatry. 2004; 65:915–918. [PubMed: 15291679]
Lewinsohn PM, Seeley JR, Hibbard J, Rohde P, Sack WH. Cross-Sectional and Prospective
Relationships between Physical Morbidity and Depression in Older Adolescents. J Am Acad Child
Adolesc Psychiatry. 1996; 35:1120–1129. [PubMed: 8824055]
March, JS. [Accessed May 19, 2006] Re: Fluoxetine for depressed adolescents: harms likely to exceed
benefits. BMJ Rapid Response to “Authors of TADS study reply to letter raising concerns”. 2005.
Available at: http://bmj.bmjjournals.com/cgi/eletters/330/7493/730-b#114574
March JS, Biederman J, Wolkow R, et al. Sertraline in children and adolescents with obsessive-
compulsive disorder: a multicenter randomized controlled trial. JAMA. 1998; 280:1752–1756.
[PubMed: 9842950]
March J, Kratochvil C, Clarke G, et al. AACAP 2002 research forum: placebo and alternatives to
placebo in randomized controlled trials in pediatric psychopharmacology. J Am Acad Child
Adolesc Psychiatry. 2004; 43:1046–1056. [PubMed: 15266201]
Olfson M, Shaffer D, Marcus SC, Greenberg T. Relationship between antidepressant medication
treatment and suicide in adolescents. Arch Gen Psychiatry. 2003; 60:978–982. [PubMed:
14557142]
Posner, K.; Oquendo, M.; Gould, M.; Stanley, B. [Accessed May19, 2006] Suicidality Classification
Project. FDA psychopharmacologic drugs advisory committee and the pediatric advisory
committee. 2004. Available at http://www.fda.gov/ohrms/dockets/ac/0A/slides/2004-4065s1.htm
Poznanski, EO.; Mokros, HB. Manual for the Children's Depression Rating Scale-Revised. Los
Angeles: Western Psychological Services; 1996.
Emslie et al. Page 16
J Am Acad Child Adolesc Psychiatry. Author manuscript; available in PMC 2012 February 23.
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t
Reynolds, WM. Professional Manual for the Suicidal Ideation Questionnaire. Lutz, FL: Psychological
Assessment Resources, Inc; 1987.
Rhee H. Physical symptoms in children and adolescents. Annu Rev Nurs Res. 2003; 21:95–121.
[PubMed: 12858694]
TADS. Treatment for Adolescents With Depression Study (TADS): rationale, design, and methods. J
Am Acad Child Adolesc Psychiatry. 2003; 42:531–542. [PubMed: 12707557]
TADS. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with
depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled
trial. JAMA. 2004; 292:807–820. [PubMed: 15315995]
TADS. The Treatment for Adolescents With Depression Study (TADS): demographic and clinical
characteristics. J Am Acad Child Adolesc Psychiatry. 2005; 44:28–40. [PubMed: 15608541]
Vitiello B, Riddle MA, Greenhill LL, et al. How can we improve the assessment of safety in child and
adolescent psychopharmacology? J Am Acad Child Adolesc Psychiatry. 2003; 42:634–641.
[PubMed: 12921470]
Wagner KD, Ambrosini PJ, Rynn M, et al. Efficacy of sertraline in the treatment of children and
adolescents with major depressive disorder. JAMA. 2003; 290:1033–1041. [PubMed: 12941675]
Wagner KD, Robb AS, Findling RL, Jin J, Gutierrez MM, Heydorn WE. A randomized, placebo-
controlled trial of citalopram for the treatment of major depression in children and adolescents.
Am J Psychiatry. 2004; 161:1079–1083. [PubMed: 15169696]
Williams PG, Colder CR, Richards MH, Scalzo CA. The role of self-assessed health in the relationship
between gender and depressive symptoms among adolescents. J Pediatr Psychol. 2002; 27:509–
517. [PubMed: 12177251]
Yates P, Kramer T, Garralda E. Depressive symptoms amongst adolescent primary care attenders.
Levels and associations. Social Psychiatry Psychiatr Epidemiol. 2004; 39:588–594.
Emslie et al. Page 17
J Am Acad Child Adolesc Psychiatry. Author manuscript; available in PMC 2012 February 23.
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t
Fig. 1.
Self-reported suicidal ideation ([SIQ-Jr] total score). FLX = fluoxetine; COMB =
combination treatment; CBT = cognitive behavioral therapy; PBO = placebo; SIQ-Jr =
Suicidal Ideation Questionnaire: Grades 7–9.
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TABLE 3
Spontaneously Reported Psychiatric Adverse Events
Symptom COMB FLX PBO CBT
Mania spectrum 1 (0.93%) 4 (3.67%) 1 (0.89%) 0 (0%)
Irritability spectrum 2 (1.86%) 4 (3.67%) 1 (0.89%) 0 (0%)
Agitation spectrum 1 (0.93%) 2 (1.84%) 2 (1.78)% 0 (0%)
Anxiety 0 (0%) 2 (1.84%) 0 (0%) 1 (0.91%)
Other 2 (1.86%) 2 (1.84%) 1 (0.89)% 0 (0%)
No. of patients 6/107 12/109 5/112 1/111
Event rate 5.6% 11.0% 4.5% 0.91%
Note: Patients may be represented in more than one column. Numbers too small to detect significant differences. COMB = combination treatment;
FLX = fluoxetine; PBO = placebo; CBT = cognitive behavioral therapy.
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ic
at
io
n
 c
o
m
p
li
an
ce
; 
C
 =
 c
o
m
p
li
an
t;
 N
C
 =
 n
o
n
co
m
p
li
an
t;
 N
A
 =
 n
o
t
ap
p
li
ca
b
le
 b
ec
au
se
 i
n
 C
B
T
 o
n
ly
; 
U
n
k
 =
 u
n
k
n
o
w
n
.
a
T
h
e 
m
o
st
 r
ec
en
t 
C
li
n
ic
al
 G
lo
b
al
 I
m
p
re
ss
io
n
s-
S
ev
er
it
y
 s
co
re
 f
o
r 
th
re
e 
su
b
je
ct
s 
w
as
 w
it
h
in
 3
 w
ee
k
s.
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